ArticleTherapeutic advances in gastroenterology2023

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.

Kira L Newman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.